共 50 条
- [31] JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLCJOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S252 - S252Jerusalem, GuyChen, FranklinSpigel, DavidIannotti, NicholasMcclay, EdwardRedfern, CharlesBennouna, JaafarTaylor, MatthewKaufman, HowardKelly, KarenChand, VikramVon Heydebreck, AnjaVerschraegen, Claire
- [32] Phase I, open-label, multi-ascending dose trial of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Shitara, KoheiYamada, YasuhideYoh, KiyotakaNaito, YoichiIwasa, SatoruYamamoto, Noboruvon Heydebreck, AnjaAchiwa, HiroyukiDoi, Toshihiko
- [33] Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Kelly, KarenPatel, Manish R.Infante, Jeffrey R.Iannotti, NicholasNikolinakos, PetrosLeach, JosephWang, DingChandler, Jason ClaudJerusalem, Guy Heinrich MariaGurtler, Jayne S.Arkenau, Hendrik-TobiasSpeit, Isabellvon Heydebreck, AnjaChin, Kevin M.Heery, Christopher RyanGulley, James L.
- [34] Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligibleANNALS OF ONCOLOGY, 2016, 27Patel, M. R.Ellerton, J.Agrawal, M.Gordon, M.Dirix, L.Lee, K-W.Infante, J.Schlichting, M.Chin, K.Apolo, B.
- [35] Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Heery, Christopher RyanCoyne, Geraldine Helen O'SullivanMarte, Jennifer L.Singh, HarpreetCordes, Lisa M.Madan, Ravi AmritDonahue, Renee NicoleGrenga, ItaliaLepone, LaurenNeuteboom, BerendSpeit, IsabellChin, Kevin M.Schlom, JeffreyGulley, James L.
- [36] Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric cancer: The phase 3 JAVELIN Gastric 100 trial.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Moehler, Markus H.Taieb, JulienGurtler, Jayne S.Xiong, HuilingZhang, JennyCuillerot, Jean-MarieBoku, Narikazu
- [37] Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Heery, Christopher RyanCoyne, Geraldine Helen O'SullivanMadan, Ravi AmritSchlom, Jeffreyvon Heydebreck, AnjaCuillerot, Jean-MarieSabzevari, HelenGulley, James L.
- [38] Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or recurrent non-small-cell lung cancer progressing after platinum-based chemotherapy: A phase Ib trialEUROPEAN JOURNAL OF CANCER, 2015, 51 : S629 - S629Gulley, J. L.Rajan, A.Spigel, D. R.Iannotti, N.Chandler, J.Wong, D. J. L.Leach, J. L.Edenfield, W. J.Wang, D.Bajars, M.Von Heydebreck, A.Kelly, K.
- [39] A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab (MSB0010718C) in patients with metastatic Merkel cell carcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Kaufman, HowardHamid, OmidD'Angelo, Sandra P.Yuan, GuojunChin, Kevin M.Bhatia, ShailenderCuillerot, Jean-MarieNghiem, Paul
- [40] Safety and clinical activity of anti-programmed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETs).JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Rajan, ArunHeery, Christopher RyanPerry, SusanKeen, CorrineMammen, Andrew L.Berman, Arlene W.Pittaluga, StefaniaLepone, Lauren MarissaDonahue, Renee NicoleGrenga, ItaliaSchlom, JeffreyHassa, RaffitGulley, James L.